hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 18:00:04 - browse：5

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Addiction experts warn against a second 'war on drugs'

WSS

Medicare coverage of Wegovy, once blocked, now looks possible

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Data integrity in scientific journals requires "effort" by publishers, institutions

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

HHS secretary Becerra pressed on Change HealthCare cyberattack

knowledge

hotspot

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Wearables generate powerful data but its not useful to doctors, yet

Medicare proposal to cover medical devices draws a mixed reaction

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Tori Bowie and the unacceptable rates of Black maternal death

HIV vaccine remains elusive. Immunologists keep trying new ideas

Tori Bowie and the unacceptable rates of Black maternal death

UCLA team creates talking throat patch for voice disorders

At least 13 dead in Texas as scorching temps continue

Helping hospitals and community health centers plan for resilience

knowledge

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Pushing for an NIH office for post

Male and female sex labels in research insufficient, scientists say

Male and female sex labels in research insufficient, scientists say

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

focus

knowledge

hotspot

focus